U.S. Paper and Forestry Products Stock News

NYSE:KRC
NYSE:KRCOffice REITs

Kilroy Realty (KRC) Valuation Check After Mixed Short Term Gains And Year To Date Share Price Decline

Recent performance snapshot Kilroy Realty (KRC) has drawn investor attention after a mixed return profile, with the stock up over the past month and past 3 months, but down year to date. Over the past month, Kilroy Realty has gained about 7%, adding to a roughly 6% rise over the past 3 months, while the stock remains about 10% lower year to date. See our latest analysis for Kilroy Realty. At a share price of $34.14, Kilroy Realty’s recent 7.3% 1 month share price return contrasts with a year...
NasdaqGS:WSBC
NasdaqGS:WSBCBanks

A Look At WesBanco (WSBC) Valuation After Expanded Buyback And Fresh Dividend Declarations

WesBanco (WSBC) has given investors fresh news to consider by expanding its stock repurchase authorization by 4.0 million shares and declaring quarterly dividends for both common and preferred shareholders. See our latest analysis for WesBanco. At a share price of $34.62, WesBanco has seen short term momentum soften, with a 30 day share price return of 3.11% and a 90 day decline of 6.05%. At the same time, a 1 year total shareholder return of 18.73% and a 3 year total shareholder return of...
NasdaqGS:LRCX
NasdaqGS:LRCXSemiconductor

Evaluating Lam Research (LRCX) Valuation After Strong Recent Share Price Performance

Lam Research (LRCX) sits at the center of the semiconductor equipment market, and its recent share performance has drawn attention as investors weigh reported returns against the company’s current revenue and profit profile. See our latest analysis for Lam Research. Over the past year, Lam Research has seen strong momentum, with the share price at US$302.24 following a 1-day share price return of 3.48% and a 30-day share price return of 16.98%. The 1-year total shareholder return of 268.77%...
NYSE:AEM
NYSE:AEMMetals and Mining

Agnico Eagle Mines (NYSE:AEM) Valuation Check After Recent Share Price Pullback

Recent performance snapshot Agnico Eagle Mines (NYSE:AEM) has drawn investor attention after a period in which the stock fell about 12% over the past month and about 22% over the past 3 months, against a backdrop of mixed return signals. See our latest analysis for Agnico Eagle Mines. The recent slide, including a 7 day share price return of down 7.74% and a 3 month share price return of down 22.13%, contrasts sharply with Agnico Eagle Mines' 1 year total shareholder return of 56.72%. This...
NasdaqGS:NUVL
NasdaqGS:NUVLBiotechs

Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus

Nuvalent plans to present pivotal clinical trial data at the 2026 ASCO Annual Meeting. The presentations include neladalkib data in ALK-positive NSCLC that supported a recent FDA NDA submission and an ongoing Phase 3 trial. The company will also share the first clinical look at zidesamtinib in ROS1-positive solid tumors, including early response data. Nuvalent (NasdaqGS:NUVL) is drawing attention ahead of ASCO 2026 as it prepares to showcase data that underpin a recent FDA NDA filing for...
NYSE:TPR
NYSE:TPRLuxury

Tapestry (TPR) Valuation Check As Patent Win For Mira Highlights In House AI Ambitions

Tapestry (TPR) has just secured a U.S. patent for Mira, its in house AI platform built to connect data across the business and support faster decisions around inventory, assortments and consumer trends. See our latest analysis for Tapestry. The patent news lands as Tapestry’s share price, now at US$139.11, reflects mixed momentum, with a 7 day share price return of 6.81% and a 30 day return that fell 7.57%, while the 1 year total shareholder return of 78.66% points to a strong longer term...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Assessing Halozyme Therapeutics (HALO) Valuation After Recent Flat Share Price And Strong Longer Term Returns

Why Halozyme Therapeutics (HALO) Is Drawing Investor Attention Now Halozyme Therapeutics (HALO) is back on investors’ radar after a period of mixed share performance, with the stock roughly flat over the past month but lower over the past 3 months. See our latest analysis for Halozyme Therapeutics. At around US$68.52, Halozyme’s recent share price moves have been relatively muted, yet the 1 year total shareholder return of 27.48% and 3 year total shareholder return of 106.76% point to longer...
NasdaqGS:MANH
NasdaqGS:MANHSoftware

Assessing Manhattan Associates (MANH) Valuation After A Mixed Share Price And Earnings Outlook

Stock performance snapshot Manhattan Associates (MANH) has been drawing attention after a mixed run in recent months, with the stock down about 20% year to date and roughly 28% over the past year. Short term performance looks different. The share price eased around 1.8% in the latest session but rose about 4.3% over the past week and has held close to flat over the past month. Over longer periods the picture has been weaker, with total returns declining about 23% over three years and roughly...
NYSE:THG
NYSE:THGInsurance

Hanover Insurance Exec Change Puts Focus On Valuation And Earnings Outlook

Hanover Insurance Group (NYSE:THG) has appointed Patricia A. Norton-Gatto as Principal Accounting Officer. The appointment reflects an internal promotion following Ms. Norton-Gatto’s long tenure and progression within the company. This move affects oversight of the company’s financial reporting and accounting functions, areas closely watched by many investors. For you as an investor, this change sits at the core of how Hanover Insurance Group presents its financial picture. As a property...
NYSE:AMH
NYSE:AMHResidential REITs

How American Homes 4 Rent’s (AMH) New Dividend Declarations May Shape Its Capital Allocation Story

Earlier this month, American Homes 4 Rent declared a US$0.33 per share cash dividend on its common stock for the second quarter of 2026, alongside quarterly cash distributions of US$0.36719 per share on its 5.875% Series G and US$0.39063 per share on its 6.250% Series H cumulative redeemable perpetual preferred shares, all payable on June 30, 2026 to shareholders of record on June 15, 2026. These dividend declarations, coming shortly before a broker rating upgrade, highlight how income...
NYSE:DOV
NYSE:DOVMachinery

Dover’s AI RF Launches At AOC Europe 2026 And What’s Priced In

Dover’s Microwave Products Group plans to launch three AI-enabled RF and electronic warfare solutions for Aerospace & Defense at AOC Europe 2026. The new products focus on radio frequency signal identification and electronic warfare capabilities for defense and aerospace customers. The launches expand Dover’s presence in advanced RF and signals intelligence technologies within a key end market. For investors tracking NYSE:DOV, these product launches come as the stock trades at $207.77, with...
NasdaqGS:WMT
NasdaqGS:WMTConsumer Retailing

Walmart (WMT) Heads Into Q1 2027 With 3.1% Net Margin Testing Rich Valuation

Walmart (WMT) opened its Q1 2027 reporting season with investors still focused on its recent run of quarterly results, which saw Q4 2026 revenue at about US$190.7b, basic EPS of US$0.53 and net income of US$4.2b. Over the last year, quarterly revenue moved from roughly US$165.6b in Q1 2026 to US$190.7b in Q4 2026, while basic EPS ranged between US$0.53 and US$0.88 as the retailer cycled through different trading periods. With trailing 12 month earnings growth of 12.6% and profit margins...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

BeOne Medicines Wins FDA Nod For BEQALZI In Mantle Cell Lymphoma

BeOne Medicines' BCL-2 inhibitor sonrotoclax (BEQALZI) has received accelerated FDA approval for relapsed or refractory mantle cell lymphoma. The decision marks a key regulatory milestone in hematology oncology for patients whose disease persists or returns after prior treatment. Sonrotoclax is also under review in additional regions and indications across hematologic malignancies. BeOne Medicines, listed as NasdaqGS:ONC, focuses on targeted therapies in hematology oncology, an area where...
NasdaqGS:BKNG
NasdaqGS:BKNGHospitality

Is It Time To Revisit Booking Holdings (BKNG) After Recent Share Price Weakness?

If you are wondering whether Booking Holdings at around US$159.68 is starting to look attractively priced or still has further to fall, the valuation picture is the key piece to focus on next. The stock has risen about 3.4% over the past week, but is still down around 16.3% over the past month, about 25.0% year to date, and about 24.7% over the last year, set against much stronger gains of 56.6% over three years and 74.2% over five years. Recent moves have come as investors reassess the...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Could Bath & Body Works’ Dividend And Earnings Revisions Reveal A Shifting Capital Playbook For BBWI?

In May 2026, Bath & Body Works, Inc. declared a quarterly dividend of US$0.20 per share, payable on June 19, 2026, with both the ex-dividend and record dates having occurred on June 5, 2026. At the same time, analysts were anticipating lower year-over-year earnings and revenue but had recently revised their profit estimates higher, highlighting a tension between softer sales trends and expectations for an earnings outperformance. Next, we’ll examine how this potential earnings surprise,...
NYSE:CWK
NYSE:CWKReal Estate

A Look At Cushman & Wakefield (CWK) Valuation As Shares Lose Recent Momentum

Recent performance snapshot Cushman & Wakefield (CWK) has drawn attention after a period where the stock is down about 12% over the past month and roughly 4% over the past 3 months, despite a positive 1 year total return. See our latest analysis for Cushman & Wakefield. At a share price of $12.82, the stock has seen its short term share price momentum fade. However, the 1 year and 3 year total shareholder returns remain firmly positive, suggesting investors are still weighing growth prospects...
NYSE:CNS
NYSE:CNSCapital Markets

CFO Transition And REIT Portfolio Overhaul Might Change The Case For Investing In Cohen & Steers (CNS)

Cohen & Steers recently overhauled its U.S. REIT portfolio, adding and exiting several positions, while also announcing Amit Muni as its next Executive Vice President and Chief Financial Officer, effective June 8, 2026. This combination of portfolio repositioning and a new finance leader signals a potential shift in how the firm manages risk, capital allocation, and future growth priorities. Next, we’ll examine how the appointment of Amit Muni as CFO could influence Cohen & Steers’ existing...
NYSE:SN
NYSE:SNConsumer Durables

Is SharkNinja (SN) Using SLUSHi Twist to Test a Higher-End, Experience-Led Brand Strategy?

Earlier this month, SharkNinja, Inc. launched the Ninja SLUSHi Twist, a dual-vessel frozen drink machine with independently powered 48‑oz containers, supported by a Snooki and JWoww “SLUSHi Sundays” promotion and limited-edition kits for the first 100 online purchasers at US$399.99. The product’s dual-flavor capability, seasonal focus on summer entertaining, and celebrity-backed social media campaign highlight how SharkNinja is using experiential marketing and differentiated appliances to...
NYSE:LOW
NYSE:LOWSpecialty Retail

Lowe’s (LOW) Net Margin Compression Challenges Bullish Narratives In Q1 2027

Lowe's Companies (LOW) opened Q1 2027 with total revenue of US$23.1b, basic EPS of US$2.90 and net income of US$1,623m, while same store sales growth came in at 0.6% for the quarter. The company has seen quarterly revenue move from US$20.9b in Q1 2026 to US$23.1b in Q1 2027, with basic EPS shifting from US$2.93 to US$2.90 over the same period. Trailing twelve month net income of US$6.6b on revenue of US$88.4b sets the backdrop for a business where margins and modest same store sales growth...
NasdaqGS:AMBA
NasdaqGS:AMBASemiconductor

Ambarella’s New AI Briefings Put Stock Narrative In Sharper Focus

Ambarella, ticker NasdaqGS:AMBA, has launched a new quarterly Industry Analyst Briefing program focused on edge and physical AI. The first session of this recurring briefing series is scheduled for June 4, 2026. The program is aimed at non financial industry analysts who influence enterprise buyers and OEMs in sectors such as automotive, IoT, security, and robotics. Ambarella enters this new outreach effort with its stock at $83.64, alongside a 39.4% return over the past 30 days and a 32.5%...
NYSE:PNC
NYSE:PNCBanks

A Look At PNC Financial Services Group’s Valuation As Mixed Returns Meet Undervalued Fair Value Estimates

How PNC Financial Services Group (PNC) Stock Has Been Moving Recent trading in PNC Financial Services Group (PNC) has drawn fresh attention to the stock, with investors weighing its mixed short term share performance against longer term total returns and current valuation signals. See our latest analysis for PNC Financial Services Group. At a share price of $218.37, PNC’s recent 7 day share price return of 2.31% contrasts with a 30 day share price return that is down 4.24%, while the 1 year...
NYSE:MOD
NYSE:MODBuilding

Is It Too Late To Consider Modine Manufacturing (MOD) After Its Huge Multi Year Rally?

Wondering whether Modine Manufacturing at around US$250 a share still offers value, or whether most of the opportunity is already priced in, is a natural question for any investor looking at this stock today. The share price has been volatile recently, declining 14.4% over the last 7 days and edging up 1.1% over 30 days, while still sitting on a 77.6% gain year to date and a 176.8% return over the last year. Recent headlines around Modine have largely focused on its rapid multi year share...
NasdaqGM:TATT
NasdaqGM:TATTAerospace & Defense

TAT Technologies (TATT) Margin Expansion To 9.4% Tests Long Term Growth Narratives

TAT Technologies (NasdaqGM:TATT) has just opened Q1 2026 earnings season with a run rate that, based on recent quarters, pairs mid forty million US$ revenue per quarter with basic EPS in the low US$0.30s. This is supported by trailing twelve month EPS of about US$1.39 on US$178.0 million of revenue and earnings growth of 50.6% over the past year. Over recent periods the company has seen revenue move from US$41.0 million in Q4 2024 to US$46.5 million in Q4 2025. Quarterly basic EPS shifted...